Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.

Novo Nordisk narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.Soaring popularity for its obesity drug has seen demand far outstrip supply and left the company racing to increase production capacity while limiting supply of start doses to ensure patients currently on the medication can continue treatment.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. When Novo’s competitor Eli Lilly reported its earnings last week,

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.